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Placental FKBP51 mediates a link 
between second trimester maternal 
anxiety and birthweight in female 
infants
Katie L. Togher  1,2,3,4, Gerard W. O’Keeffe1,2,4, Ali S. Khashan1,5, Gerard Clarke1,2,6 & 
Louise C. Kenny7
Prenatal distress is associated with adverse outcomes in affected offspring. Alterations in placental 
glucocorticoid signalling and subsequent foetal overexposure to glucocorticoids have been implicated 
as an underlying mechanism. Infant sex is emerging as an important factor in disease susceptibility. 
This study aimed to examine the effects of maternal distress across pregnancy on birth outcomes 
and placental glucocorticoid genes in a sex-dependent manner. Participants completed psychological 
distress questionnaires throughout pregnancy. Placental HSD11B2, NR3C1 and FKBP51 were analysed 
by real time PCR and cortisol was measured in new-born hair. Second trimester stress was negatively 
correlated with birthweight in males and positively correlated with placental NR3C1 mRNA in females. 
Second trimester anxiety was negatively correlated with birthweight and placental FKBP51 mRNA 
in females. In mediation analysis, placental FKBP51 mRNA expression was found to mediate the link 
between prenatal anxiety and birthweight. New-born cortisol was negatively correlated with second 
trimester anxiety and positively correlated with female placental FKBP51 mRNA levels. Again, FKBP51 
mRNA was found to mediate the link between anxiety and new-born cortisol. These results highlight a 
role for FKBP51 in the placental response to prenatal distress in females. The precise role that placental 
FKBP51 has in foetal and infant development has not been extensively studied and warrants further 
investigations.
There is now a large body of evidence showing that the in utero experience is a critical determinant of future 
health1–3. One factor that has been extensively studied in this regard is the adverse effects of prenatal maternal 
psychological distress, which we define as the experience of significant levels of psychological stress, depression, 
and/or anxiety during pregnancy4,5. We have previously reported the incidence of this in pregnancy using the 
SCOPE (Screening for Pregnancy Endpoints) pregnancy cohort of nulliparous healthy pregnant women6,7. All 
participants completed a combination of validated questionnaires used to assess maternal psychological distress5. 
These included the 10-item Perceived Stress Scale (PSS) to measure psychological stress8, the 6-item version of 
State Trait Anxiety Inventory (STAI) to measure maternal anxiety9, and the Edinburgh Postnatal Depression Scale 
(EPDS) to measure maternal depressive symptoms in pregnancy8,10. We found that 15% of women experienced 
‘very high levels of perceived psychological stress (≥90th percentile score), 18% were classified as being as ‘very 
highly anxious’ (≥90th percentile score), while 15% were classified as being ‘highly likely depressed’ (EPDS score 
>9)5. Collectively these data have shown that approximately one in seven women experience clinically significant 
levels of prenatal maternal psychological distress during pregnancy.
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This is important as numerous epidemiological studies have reported that exposure to prenatal maternal psy-
chological distress is a risk factor for a range of adverse short and long-term outcomes in affected offspring. 
These include an increased risk of adverse obstetric outcomes including caesarean delivery, preterm birth (PTB), 
low birth weight (LBW) and babies who are small for gestational age (SGA)4,5,11–14. Moreover prenatal maternal 
psychological distress has been proposed to be a risk factor for the development of immune15,16, metabolic17,18 
and neuropsychiatric disorders19–21 later in life, with the relative risk varying by offspring sex20,22–24. These stud-
ies highlight the importance of prenatal maternal psychological distress as a risk factor for adverse outcomes in 
exposed offspring; however, the causal pathways mediating these associations are unclear.
The glucocorticoid hypothesis is the most widely studied biological mechanism proposed to mediate the asso-
ciation between prenatal maternal psychological distress and adverse outcomes25. During pregnancy, changes in 
the maternal hypothalamic-pituitary-adrenal (HPA) axis leads to an exponential rise in cortisol in the maternal 
circulation26,27. This cortisol stimulates the release of corticotrophin releasing hormone (CRH) from the placenta 
that enters the maternal circulation and further increases the production of cortisol forming a feed forward loop. 
As a result maternal cortisol levels are up to ten-fold higher than foetal levels28. This progressive increase in 
maternal cortisol is necessary for foetal organogenesis, however excessive foetal exposure may alter developmen-
tal trajectories29. The maternal-foetal cortisol gradient is maintained by the expression of 11β-hydroxysteroid 
dehydrogenase type 2 (HSD11B2) in the placental trophoblast which converts active cortisol into inactive cor-
tisone29. Additionally, the glucocorticoid receptor (NR3C1) and FKPB51, a chaperone protein which regulates 
nuclear transport of NR3C130, play an important role in the foetal response to cortisol. We and others have shown 
that maternal distress in late pregnancy reduces placental HSD11B2 expression4,31,32. We also found that the 
glucocorticoid receptor NR3C1 is upregulated by third trimester distress4. Increased methylation of placental 
FKBP51 has been reported following early third trimester stress33, however we previously observed no change 
in FKBP51 expression following distress in the third trimester4, indicating the need to examine other trimesters. 
Collectively these data suggest that prenatal maternal psychological distress may alter molecular mechanisms 
that regulate foetal exposure to maternal cortisol. Importantly alterations in the expression and regulation of 
HSD11B2, NR3C1 and/or FKBP51 has been linked to poor birth outcomes34–36 as well as neurobehavioral prob-
lems in infants37–40, suggesting that these may play a causal role in mediating the association between maternal 
distress and adverse outcomes.
In this study we sought to examine the relationships between psychological prenatal distress in the second and 
third trimester of pregnancy with birth outcomes and placental HSD11B2, NR3C1 and FKBP51 expression, as 
three key mediators of placental cortisol signalling. Moreover, we undertook causal mediation analysis to deter-
mine whether any changes in the placental expression of these genes were associated with birth outcomes using 
gender-sensitive methodology.
Results
Study Population. As part of a longitudinal cohort study at Cork University Maternity Hospital, 121 nul-
liparous pregnant women were recruited in their first or early second trimester of pregnancy. Placenta samples 
were available for 56 women. Detailed medical records were available for 55 of these women. 51 participants 
completed the PSS, STAI and EPDS in the second trimester (mean = 20.37 ± 0.85 gestational weeks (GW)). 46 
participants completed these questionnaires in the third trimester (mean = 32.62 ± 1.03 GW) (Supplementary 
Fig. S1). New-born hair samples were available for 29 infants (51.8%). The mean ± SD PSS, STAI and EPDS 
scores were 14.41 ± 5.19, 4.87 ± 3.49 and 6.31 ± 4.16 in the second trimester and 12.13 ± 5.62, 5.27 ± 3.13 and 
6.30 ± 4.63 in the third trimester respectively (Supplementary Fig. S2). Descriptive statistics for this cohort are 
presented in Tables 1 and 2.
Exposure to second trimester maternal anxiety negatively affects female birth weight. We 
first sought to determine whether maternal psychological distress scores affected infant birth weight. To do this 
we examined the associations between PSS, STAI and EPDS scores in the second and/or third trimester with 
birth weight (mean = 3623 ± 460.3 g) (n = 55). We found that PSS scores in the second trimester were negatively 
correlated with male (p < 0.05), but not female birth weight (Fig. 1a,b). We found no associations between PSS 
scores measured in the third trimester or combined across pregnancy with male or female birth weight (Table 3). 
In contrast, second trimester STAI scores were negatively correlated with female (p < 0.05) but not male birth 
weight (Fig. 1c,d). We found no associations between STAI scores in the third trimester and birth weight in male 
or female infants (Table 3). When combined across pregnancy, STAI scores were negatively correlated with female 
Mean ± SD Range N
Maternal Age 30.80 ± 4.61 19–41 55
Maternal BMI 25.11 ± 4.15 19–39 55
Gestational Age (weeks) 39.75 ± 0.16 34–42 55
1 min Apgar Score 8.36 ± 0.18 3–10 55
5 min Apgar Score 9.51 ± 0.09 6–10 55
Birthweight 3623.45 ± 62.07 2170–4980 55
Birthweight Centiles 54.13 ± 3.48 9–100 55
Table 1. Descriptive statistics of continuous variables. Abbreviations: Standard Deviation (SD), Body Mass 
Index (BMI).
www.nature.com/scientificreports/
3SCIeNTIFIC RepORTs |  (2018) 8:15151  | DOI:10.1038/s41598-018-33357-3
birthweight (Table 3). We observed no association between EPDS scores in the second and/or third trimester 
with birth-weight of infants of either sex (Table 3). As infant birth weight was significantly altered by maternal 
BMI (Supplementary Table 1), we adjusted our regression model to examine the potential confounding effects 
of maternal BMI. When BMI was included in the analyses, the relationship between second trimester PSS scores 
and male birth weight disappeared (aβ = −0.32, t (23) = −1.72, p = 0.099). In contrast, second trimester anxiety 
remained correlated with female birth weight when BMI was included in the regression model (aβ = −0.46, 
t (26) = −2.71, p = 0.012). These data revealed a gender specific effect of maternal anxiety on birth weight in 
female infants.
Placental FKBP51 mediates the association between second trimester maternal anxiety and 
female birth weight. As second trimester anxiety was associated with female birth weight, we next exam-
ined the relationship between second trimester STAI scores and three key genes involved in glucocorticoid sig-
nalling in the placenta, HSD11B2, NR3C1 and FKBP51. In agreement with our findings on female birth weight 
(Fig. 1), we found a significant negative correlation between second trimester STAI scores and placental FKBP51 
expression in females (β = −0.64, t (25) = −4.10, p < 0.0001), but not males (β = −0.53, t (23) = −1.78, p = 0.09). 
We found no significant associations between STAI scores in the second and/or third trimester and HSD11B2 or 
NR3C1 expression in males or females (Table 4). Additionally, no associations were observed between PSS and 
EPDS scores in the second or/and third trimester and placental expression of HSD11B2, NR3C1 and FKBP51 
(Table 4), indicating that this effect is specific to heightened anxiety levels. We subsequently examined if placen-
tal FKBP51 expression was an independent predictor of infant birth weight. There was a significant association 
between placental FKBP51 with birth weight in female (β = 0.54, t (29) = 3.38, p = 0.002) but not male (β = −0.16, 
t (24) = −0.78, p = 0.44) infants (Table 5). These data show that second trimester anxiety (STAI scores) negatively 
correlates with both birth weight and placental FKBP51 in females, and that FKBP51 positively correlates with 
birth weight in females. Given these findings, we hypothesised that placental FKBP51 may be mediating the 
relationship between maternal anxiety and female birth weight. In support of this hypothesis when FKBP51 
was included into the regression model the association between maternal anxiety and female birth weight was 
reduced (β = 0.19, t (25) = −0.816, p = 0.423) (Fig. 2a). These data show that the association between second 
trimester maternal anxiety and female birth weight is mediated by placental FKBP51 (Figs 2 and 3).
Alterations in second trimester maternal anxiety and placental FKBP51 are associated with 
new-born cortisol levels. The placental and foetal response to glucocorticoids is crucial in determining 
foetal growth outcomes. This is highlighted by studies showing that exposure to synthetic glucocorticoids during 
Frequency (%) N
Marital Status
Single 12.7 7
Married 52.7 29
Defacto 34.5 19
Employment
Full-time 87.3 48
Part-time 5.5 3
Unemployed 7.3 4
Country of Birth
Ireland 83.6 46
United Kingdom 5.5 3
Poland 5.5 3
Brazil 1.8 1
Spain 1.8 1
Romania 1.8 1
Parity
Nulliparous 100 55
Multiparous 0 0
Mode of Delivery
Unassisted vaginal 41.8 23
Operative vaginal 36.4 20
Prelabour LSCS 9.1 5
LSCS in labour 12.7 7
Infant sex
Male 45.5 25
Female 54.5 30
Gestational Age
Term (>38 wks) 98.2 54
Preterm (<37 wks) 1.8 1
Gestational Size
SGA 1.8 1
AGA 90.9 50
LGA 7.3 4
Table 2. Descriptive statistics of categorical variables. Abbreviations: Lower Segment Caesarean Section 
(LSCS), SGA (Small for Gestational Age (SGA), Average for Gestational Age (AGA), Large for Gestational Age 
(LGA).
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pregnancy is associated with reductions in birth weight41, with some sex-specific outcomes also observed42. As 
FKBP51, negatively regulates nuclear transport of NR3C130, we hypothesized that this may result in alterations in 
cortisol levels in infants. In an exploratory technique we measured cortisol levels in new-born hair as a potential 
retrospective measure of cortisol exposure in utero43. New-born hair samples were available for 29 infants in this 
cohort. We examined the relationship between maternal distress and infant cortisol levels. Maternal PSS or EPDS 
scores in the second and/or third trimester did not correlate with infant cortisol levels (Table 6). Surprisingly 
however, second trimester maternal anxiety (STAI) was negatively associated with infant hair cortisol levels 
(β = −0.43, t (25) = −2.33, p = 0.028). We next went on to examine the relationship between placental genes 
and birth outcomes with infant cortisol. Placental HSD11B2 (β = −0.02, t (28) = −0.10, p = 0.920) and NR3C1 
(β = −0.19, t (28) = −1.00, p = 0.325) were not related to new-born cortisol. Intriguingly however, FKBP51 
expression was positively correlated with infant cortisol levels in females only (β = 0.54, t (13) = 2.23, p = 0.045). 
As both maternal anxiety and FKBP51 were related to new-born cortisol levels, when we included both in a 
mediation model, the relationship between second trimester anxiety (aβ = −0.27, t (11) = −0.62, p = 0.550) and 
FKBP51 (aβ = 0.30, t (11) = 0.68, p = 0.510) with new-born cortisol levels was reduced. These data suggest that 
FKBP51 mediates the relationship between second trimester anxiety and new-born cortisol levels (Fig. 2b). As 
the relationship between second trimester anxiety and infant birthweight and cortisol levels were both inde-
pendently mediated by placental FKBP51, we hypothesized that foetal cortisol may be the biological mediator 
behind these associations. However, there was no correlation observed between new-born cortisol levels and 
infant birth weight, suggesting the biological mediators linking placental FKBP51 with infant birthweight may 
not be related to foetal cortisol exposure.
Figure 1. Second trimester distress correlates with reduced infant birthweight. Scatter plots of birthweight and 
(a,b) second trimester stress (PSS) and (c,d) second trimester anxiety (STAI) in males (blue) and females (red). 
Univariate linear regression analysis *p < 0.05.
www.nature.com/scientificreports/
5SCIeNTIFIC RepORTs |  (2018) 8:15151  | DOI:10.1038/s41598-018-33357-3
Discussion
A large proportion of women report experiencing psychological distress throughout their pregnancy5,32. This is 
important as prenatal distress has been linked to a wide range of poor obstetric and neonatal outcomes as well as 
an increased risk of disease in childhood and adulthood for exposed offspring. Of particular importance prenatal 
distress is commonly linked to birthweight and birth size44. Reduced birthweight remains a significant clinical 
challenge as it is often associated with increased mortality and morbidity45. Additionally, infants of lower birth-
weights are at an increased risk of developmental impairments in childhood, particularity in relation to neurode-
velopment46,47. Whilst the poor outcomes associated with being born low birthweight are well documented, the 
prenatal determinants linking psychological distress and birthweight are not very well understood.
Here we find the effect of maternal distress on birth outcomes to depend on the type of distress, timing of 
distress and sex of the infant. We initially observed a significant relationship between second trimester stress and 
reduced infant birthweight in males. However, this association disappeared after adjustment for maternal BMI. 
Most notably we observe a significant negative correlation between birthweight and second trimester anxiety, 
consistent with a recent report48. When stratified based on sex, this relationship was only observed in females. 
This sex difference pertaining to birthweight and prenatal anxiety has previously been reported where males born 
from anxious pregnancies had increased birthweight compared to male controls, and females born from anxious 
mothers had reduced birthweights compared to female controls49. Anxious mothers of females are more likely 
to develop obstetric complications, whereas anxious mothers of males are not50. Male fetuses are generally more 
vulnerable to the effects of maternal distress51. It has been postulated that under conditions of adversities the male 
fetus favors growth at the expense of other developmental processes, whereas the female fetus conserves growth, 
thus being born at lower weights but with fewer morbidities in later life50. In support of this, mid pregnancy 
exposure to dexamethasone, a synthetic glucocorticoid, was found to decrease maternal blood in sinusoids of 
the female but not male placenta, restricted blood flow may mechanistically explain restricted growth in female 
fetuses52.
At a biological level, sex specific responses in the placenta to maternal perturbations may explain why one sex 
is more vulnerable over the other53. Sex-specific responses to maternal glucocorticoids, or more specifically how 
the placenta regulates glucocorticoids differentially may play a role54,55. In this study we focused on three genes in 
the placenta involved in glucocorticoid regulation; HSD11B2, NR3C1 and FKBP51. Inconsistent with our previ-
ous work4 and work of others31, we do not observe a reduction in HSD11B2 following prenatal distress, however 
Both Males Females
PSS (2nd trimester)
Birthweight β = −0.18, t50 = −1.32, p = 0.19 β = −0.40, t23 = −2.08, p = 0.04 β = −0.05, t26 = −0.25, p = 0.79
Birthweight Centiles β = −0.18, t50 = −1.29, p = 0.20 β = −0.30, t23 = 1.50, p = 0.14 β = −0.16, t26 = −0.82, p = 0.41
PSS (3rd trimester)
Birthweight β = −0.10, t45 = −0.71, p = 0.47 β = −0.24, t20 = −1.08, p = 0.29 β = −0.05, t24 = −0.25, p = 0.80
Birthweight Centiles β = −0.05, t45 = −0.37, p = 0.70 β = −0.15, t20 = −0.67, p = 0.50 β = 0.00, t24 = 0.01, p = 0.99
PSS (Combined)
Birthweight β = −0.266, t41 = −1.75, p = 0.09 β = −0.40, t19 = −1.87, p = 0.08 β = −0.22, t21 = −0.22, p = 0.34
Birthweight Centiles β = −0.20, t41 = −1.331, p = 0.19 β = −0.29, t19 = −1.32, p = 0.20 β = −0.19, t21 = −0.86, p = 0.40
STAI (2nd trimester)
Birthweight β = −0.25, t50 = −1.85, p = 0.07 β = 0.08, t23 = 0.39, p = 0.69 β = −0.43, t26 = −2.42, p = 0.02
Birthweight Centiles β = −0.19, t50 = −1.41, p = 0.16 β = −0.00, t23 = −0.02, p = 0.97 β = −0.34, t26 = −1.80, p = 0.08
STAI (3rd trimester)
Birthweight β = −0.28, t45 = −1.95, p = 0.05 β = −0.18, t20 = −0.81, p = 0.42 β = −0.33, t24 = −1.70, p = 0.10
Birthweight Centiles β = −0.19, t45 = −1.33, p = 0.18 β = −0.19, t20 = −0.84, p = 0.40 β = −0.23, t24 = −1.17, p = 0.25
STAI (Combined)
Birthweight β = −0.36, t41 = −2.41, p = 0.02 β = −0.05, t19 = −0.22, p = 0.83 β = −0.50, t21 = −2.59, p = 0.02
Birthweight Centiles β = −0.26, t41 = −1.73, p = 0.09 β = −0.15, t19 = −0.64, p = 0.53 β = −0.37, t21 = −1.79, p = 0.09
EPDS (2nd trimester)
Birthweight β = −0.13, t50 = −0.95, p = 0.34 β = −0.15, t23 = −0.72, p = 0.47 β = −0.13, t26 = −0.69, p = 0.49
Birthweight Centiles β = −0.09, t50 = −0.69, p = 0.49 β = −0.22, t23 = −1.06, p = 0.29 β = −0.10, t26 = −0.51, p = 0.60
EPDS (3rd trimester)
Birthweight β = −0.12, t45 = −0.85, p = 0.39 β = −0.08, t20 = −0.37, p = 0.70 β = −0.14, t24 = −0.72, p = 0.47
Birthweight Centiles β = −0.06, t45 = −0.39, p = 0.69 β = −0.08, t20 = −0.35, p = 0.73 β = −0.03, t24 = −0.15, p = 0.87
EPDS (Combined)
Birthweight β = −0.21, t41 = −1.37, p = 0.18 β = −0.12, t19 = −0.53, p = 0.61 β = −0.27, t21 = −1.26, p = 0.22
Birthweight Centiles β = −0.11, t41 = −0.72, p = 0.48 β = −0.20, t19 = −0.87, p = 0.39 β = −0.12, t21 = −0.56, p = 0.58
Table 3. Maternal distress across pregnancy and birth outcomes. Linear regression analysis. Data shown are 
crude unstandardized betas with corresponding t-statistic and p-values. Abbreviations: Perceived Stress Scale 
(PSS), State Trait Anxiety Inventory (STAI) and Edinburgh Postnatal Depression Scale (EPDS).
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the mean stress score in this population was relatively low and the effect of maternal stress on HSD11B2 expres-
sion has been shown to be dependent on severity56. Second trimester maternal stress increased NR3C1 expression 
in female placentae. This increase in NR3C1 we observe among females but not males could again represent an 
adaptive response of the female placenta in response to maternal distress.
FKBP51 is a chaperone protein that interacts with steroid hormone receptors through heat shock protein 90 
(HsP90), inhibiting the activation of the glucocorticoid receptor and the progesterone receptor (PR) and increas-
ing the activation of the androgen receptor57. Consistent with previous reports33,58 we find prenatal distress to 
reduce placental FKBP51 expression. Importantly we find placental FKBP51 to mediate a relationship between 
second trimester anxiety and infant birth weight in females only, suggesting a critical role for this chaperone 
protein in the female foetal response to maternal anxiety. As FKBP51 regulates the glucocorticoid receptor we 
hypothesised that placental changes in FKBP51 would result in alterations in foetal cortisol. Indeed, we observed a 
positive correlation between placental FKBP51 and new-born cortisol levels in female infants. Of interest, second 
trimester anxiety was the only distress variable that influenced new-born cortisol levels. Following our mediation 
analysis, we showed second trimester maternal anxiety decreases new-born cortisol levels by reducing FKBP51 
in female placentae (Fig. 3). However, no association between new-born cortisol levels and birthweight were 
found. Alternatively, the inhibitory action of FKBP51 on the PR may underlie the relationship between maternal 
anxiety and infant birthweight. Progesterone supplementation is commonly administered to women at risk of 
preterm birth and women who receive progesterone are less likely to deliver a preterm or deliver low birthweight 
Both Males Females
PSS (2nd trimester)
HSD11B2 β = 0.26, t49 = 1.89, p = 0.07 β = 0.39, t22 = 1.99, p = 0.06 β = 0.09, t26 = 0.47, p = 0.64
NR3C1 β = −0.11, t50 = 0.80, p = 0.43 β = −0.15, t23 = −0.71, p = 0.49 β = 0.42, t26 = 2.33, p = 0.03
FKBP5 β = −0.05, t49 = −0.32, p = 0.75 β = −0.04, t23 = −0.17, p = 0.87 β = −0.09, t25 = −0.42, p = 0.68
PSS (3rd trimester)
HSD11B2 β = −0.11, t45 = −0.71, p = 0.48 β = −0.20, t20 = −0.90, p = 0.38 β = −0.02, t24 = −0.11, p = 0.92
NR3C1 β = −0.21, t45 = −1.39, p = 0.17 β = −0.31, t20 = −1.44, p = 0.17 β = −0.21, t24 = −0.59, p = 0.55
FKBP5 β = −0.16, t44 = −1.05, p = 0.29 β = −0.12, t20 = −0.53, p = 0.60 β = −0.21, t23 = −1.04, p = 0.32
PSS (Combined)
HSD11B2 β = 0.13, t41 = 0.81, p = 0.42 β = 0.15, t19 = 0.64, p = 0.53 β = 0.08, t21 = 0.34, p = 0.74
NR3C1 β = −0.10, t41 = −0.65, p = 0.52 β = −0.39, t19 = −1.84, p = 0.08 β = 0.17, t21 = 0.81, p = 0.43
FKBP5 β = −0.14, t40 = −0.89, p = 0.38 β = −0.05, t19 = −0.23, p = 0.82 β = −0.28, t20 = −1.31, p = 0.20
STAI (2nd trimester)
HSD11B2 β = −0.12, t49 = −0.81, p = 0.42 β = −0.12, t22 = −0.54, p = 0.59 β = −0.11, t26 = −0.56, p = 0.58
NR3C1 β = 0.15, t50 = 1.04, p = 0.31 β = 0.17, t23 = 0.78, p = 0.44 β = 0.13, t26 = 0.66, p = 0.52
FKBP5 β = −0.46, t49 = −3.59, p = 0.001 β = −0.36, t23 = −1.79, p = 0.08 β = −0.64, t25 = −4.10, p = 0.000
STAI (3rd trimester)
HSD11B2 β = −0.00, t45 = −0.02, p = 0.98 β = −0.00, t20 = −0.03, p = 0.98 β = −0.01, t24 = −0.06, p = 0.95
NR3C1 β = −0.02, t45 = −0.14, p = 0.89 β = −0.01, t20 = −0.08, p = 0.94 β = −0.02, t24 = −0.09, p = 0.92
FKBP5 β = −0.21, t44 = −1.40, p = 0.17 β = −0.14, t20 = −0.61, p = 0.55 β = −0.31, t23 = −1.51, p = 0.15
STAI (Combined)
HSD11B2 β = −0.04, t41 = −0.23, p = 0.82 β = −0.01, t19 = −0.05, p = 0.96 β = −0.06, t21 = −0.27, p = 0.79
NR3C1 β = 0.06, t41 = −0.40, p = 0.68 β = 0.06, t19 = 0.26, p = 0.79 β = 0.07, t21 = −0.30, p = 0.77
FKBP5 β = −0.36, t40 = −2.43, p = 0.019 β = −0.26, t19 = −1.17, p = 0.26 β = −0.53, t20 = −2.70, p = 0.01
EPDS (2nd trimester)
HSD11B2 β = 0.09, t49 = 0.67, p = 0.50 β = 0.06, t22 = 0.27, p = 0.79 β = 0.08, t26 = 0.39, p = 0.69
NR3C1 β = 0.03, t50 = 0.19, p = 0.85 β = −0.13, t23 = −0.63, p = 0.54 β = 0.16, t26 = 0.82, p = 0.42
FKBP5 β = −0.26, t49 = −1.83, p = 0.07 β = −0.24, t23 = −1.16, p = 0.26 β = −0.34, t25 = −1.74, p = 0.09
EPDS (3rd trimester)
HSD11B2 β = −0.05, t45 = −0.34, p = 0.74 β = 0.08, t20 = 0.33, p = 0.75 β = −0.15, t24 = −0.72, p = 0.48
NR3C1 Β = −0.19, t45 = −1.25, p = 0.22 β = −0.24, t20 = −1.08, p = 0.29 Β = −0.16, t24 = −0.76, p = 0.46
FKBP5 β = −0.14, t44 = −0.92, p = 0.36 β = 0.07, t20 = 0.35, p = 0.73 β = −0.40, t23 = −2.09, p = 0.051
EPDS (Combined)
HSD11B2 β = 0.06, t41 = 0.36, p = 0.72 β = 0.16, t19 = 0.67, p = 0.51 β = −0.06, t21 = −0.28, p = 0.78
NR3C1 Β = −0.12, t41 = −0.75, p = 0.46 β = −0.26, t19 = −1.17, p = 0.26 β = −0.00, t21 = −0.00, p = 0.99
FKBP5 β = −0.19, t40 = −1.27, p = 0.21 β = −0.02, t19 = −0.10, p = 0.92 β = −0.44, t20 = −2.16, p = 0.04
Table 4. Maternal distress across pregnancy and placental HSD11B2, NR3C1 and FKBP51 expression. Linear 
regression analysis. Data shown are crude unstandardized betas with corresponding t-statistic and p-values. 
Abbreviations: Perceived Stress Scale (PSS), State Trait Anxiety Inventory (STAI) and Edinburgh Postnatal 
Depression Scale (EPDS).
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infants59. As the relationship we observed between placental FKBP51 and birthweight was specific to females, 
it is of particular interest that increased maternal serum placental progesterone in the first trimester has been 
found to be associated with increased birthweight in females, with no significant effect on males60. Therefore, it 
may be possible that the inhibitory actions of FKBP51 on the PR may underlie the link between maternal anxiety 
and female birthweight. Future studies into this relationship should help to elucidate these mechanisms. None 
the less our finding, together with the previously reported relationship between placental FKBP51 methylation 
and neurobehavioral problems in infants40, suggests placental FKBP51 as a novel player in foetal programming.
Identifying vulnerable periods of development where the foetus (and placenta) are most susceptible to envi-
ronmental perturbations is a growing area of research. By prospectively examining women in the second and 
third trimester we have been able to identify the second trimester as a critical window where the foetus might be 
most susceptible to the effects of maternal anxiety. This is consistent with a number of similar studies that have 
demonstrated alterations in the mRNA expression and/or methylation levels of glucocorticoid regulating genes, 
following second trimester maternal distress31,33,61. Similarly, mid-gestation exposure to severe life events, par-
ticularly in months 5 and 6 of pregnancy have been shown to heighten the risk of adverse neonatal outcomes62. 
The vulnerability of the second trimester is further evident by a number of studies that have shown second tri-
mester stress to predict poor neurodevelopment in infants63–66. The second trimester is a period of rapid foetal 
growth, particularly for the foetal brain67. Further, the foetal HPA response becomes active from 20 weeks of preg-
nancy68, therefore maternal stress arising in this period may have a more detrimental impact on development.
The current study has several strengths and limitations. Although the sample size used in this study is com-
parable to that of previously published work examining maternal distress and placental gene expression31,32, we 
acknowledge the small sample size and suggest this research be carried out on a larger scale, although appreciate 
the difficulties in running large scale placental collection studies for mRNA analysis69. Due to the limited sample 
size in this cohort, we did not routinely adjust for potential confounders outside of maternal age and BMI, there-
fore it may be possible that maternal lifestyle factors and socioeconomic status may be further influencing this 
relationship. We report significant associations with prenatal distress and birthweight we would like to highlight 
that only one (1.8%) infant in this cohort was born <2500 g, the WHO estimate for clinically defined low birth-
weight70. Validating this work in a cohort of clinically defined low birthweight infants will be an important next 
step in unravelling the role of FKBP51 in the foetal response to maternal anxiety. By prospectively examining 
maternal distress in the second and third trimester of pregnancy we have been able to identify the second trimes-
ter as a crucial period during development whereby the foetus may be most susceptible to the effects of maternal 
distress. This will add to the growing body of literature examining critical windows of foetal development.
Overall this study is important as it identifies a crucial role for the timing of distress, the type of distress and 
foetal sex in the relationship between prenatal distress and placental gene expression. This adds to the existing 
literature supporting a role for alterations in placental glucocorticoid signalling following prenatal distress. To 
our knowledge this is the first study to identify an association between placental FKBP51 and infant birthweight. 
Importantly we identify this gene to be a key mediator underlying a relationship between prenatal anxiety and 
birthweight in females, which highlights the crucial role placental signalling has in terms of exposure to maternal 
distress and infant development. The identification of this relationship warrants further investigation into the 
precise role that FKBP51 has in foetal development.
Methods
Participants. This study received full ethical approval from the Clinical Research Ethics Committee of Cork 
Teaching Hospitals and was carried out in accordance with the guidelines and regulations outlined in the ethics. 
Nulliparous pregnant women enrolled in the IMPROvED study71 at Cork University Maternity Hospital were 
invited to participate in this study. After giving informed consent, participants completed the PSS, STAI, and 
EPDS in the second and/or third trimesters of pregnancy. Detailed demographic and medical information was 
acquired from the participants’ medical records.
New-born Hair Collection and Processing. New-born hair was acquired from the posterior vortex of the 
new-borns head within 24 h of birth and stored at room temperature until processing. 1 mg of hair was incubated 
in 1 ml of methanol at 50 °C for 24 h. Samples were sonicated for 30 min at 37 °C followed by another incubation 
Both Males Females
HSD11B2
Birthweight β = 0.05, t53 = 0.36, p = 0.72 β = −0.17, t23 = −0.81, p = 0.42 β = 0.14, t29 = 0.76, p = 0.45
Birthweight Centiles β = 0.14, t53 = 1.04, p = 0.30 β = −0.07, t23 = −0.36, p = 0.71 β = 0.21, t29 = 1.17, p = 0.24
NR3C1
Birthweight β = −0.07, t54 = −0.55, p = 0.58 β = −0.05, t24 = −0.24, p = 0.80 β = 0.09, t29 = −0.47, p = 0.63
Birthweight Centiles β = −0.16, t54 = −1.24, p = 0.21 β = −0.03, t24 = −0.15, p = 0.87 β = −0.26, t29 = −1.43, p = 0.16
FKBP51
Birthweight β = 0.21, t53 = 1.58, p = 0.11 β = −0.16, t24 = −0.78, p = 0.44 β = 0.54, t29 = 3.38, p = 0.002
Birthweight Centiles β = 0.21, t53 = 1.57, p = 0.122 β = −0.09, t24 = −0.43, p = 0.67 β = 0.56, t29 = 3.51, p = 0.002
Table 5. Placental HSD11B2, NR3C1 and FKBP51 expression and neonatal outcomes. Linear regression 
analysis. Data shown are crude unstandardized betas with corresponding t-statistic and p-values.
www.nature.com/scientificreports/
8SCIeNTIFIC RepORTs |  (2018) 8:15151  | DOI:10.1038/s41598-018-33357-3
for 24 h at 50 °C. The supernatant was removed and evaporated under nitrogen and the pellet was resuspended in 
Phosphate Buffered Solution. Cortisol concentration was determined by ELISA as per the manufacturer’s instruc-
tions (Enzo life Sciences).
Placental collection and real-time PCR. Placenta biopsies were collected from 56 participants within 
2 h of delivery, washed in dH2O and immediately stored at −80 °C. RNA was extracted from placental samples 
using Trizol reagent as previously described4. Briefly, placental samples were homogenised in Trizol and left on 
ice for 10 min. Samples were centrifuged and the supernatant was incubated in chloroform at room temperature 
for 5 min followed by centrifugation for 15 min at 4 °C to remove the aqueous phase. RNA was isolated by incu-
bation of the aqueous phase with propanol at room temperature for 10 min. Samples were centrifuged and the 
pellet washed in 70% ethanol before resuspension in RNAse free H2O (Sigma). RNA quality and quantity were 
determined by the Nanodrop 1000. RNA was reverse transcribed into cDNA (400 ng/ml) using the high capacity 
cDNA reverse transcription kit (Applied Biosystems) under the following parameters: 25 °C for 10 min, 37 °C for 
Figure 2. Placental FKBP51 mediates the relationship between prenatal anxiety and birthweight in females. 
Mediation Plots (a) Placental FKBP51 mediates the relationship between second trimester maternal anxiety 
and infant birthweight in females. (b) Placental FKBP51 mediates the relationship between second trimester 
maternal anxiety and new-born hair cortisol in females. Linear regression analysis.
Figure 3. Summary Figure. Second trimester maternal anxiety decreases infant birthweight in female offspring 
by inhibiting placental FKBP51. Similarly second trimester maternal anxiety reduced foetal cortisol exposure by 
inhibiting FKBP51 in female offspring.
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120 min, 85 °C for 5 min and 4 °C for at least 10 min. Real time PCR was performed with the following targets; 
GAPDH, HSD11B2, NR3C1 and FKBP51 (Integrated DNA Technologies; IDT) using the following parameters; 
50 °C for 2 min, 95 °C for 10 min, 50 repetitions of 95 °C for 15 s and annealing/elongating at 60 °C, as previously 
described4. All samples were run in triplicate and gene expression was determined using the 2−ΔΔcycle thresh-
old (2dCT) method72 with GAPDH as the reference.
Statistical Analysis. Data analysis was performed on SPSS v22. Scatterplots were produced using R v3.4.2, 
library ggplot2. Normality of predictor and outcome variables were tested for using Kolmogorov-Smirnov tests. 
Questionnaire scores, birthweight and birthweight centiles were normally distributed. Placental gene expres-
sion and hair cortisol levels displayed a non-normal distribution and were log transformed prior to analysis 
(Supplementary Fig. S3). A cumulative stress, depression and anxiety score was determined for each participant 
by summing relevant questionnaire scores from the second and third trimester. This cumulative score is referred 
to as PSS, STAI or EPDS combined throughout the results section. Outliers were determined using a Grubbs test 
and removed if p < 0.05. Relationships were determined using linear regression analysis. Due to the limited sam-
ple size in this cohort, regression models were adjusted for maternal age and BMI, only when these demographics 
correlated with the predictor and/or outcome variables (p < 0.05) (Supplementary Table S1).
Data Availability
The raw data used to complete this work is available to readers in Supplementary Information, Supplementary 
Table S3.
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